 |
|
Plan B and the Politics of Doubt
Frank Davidoff, MD;
James Trussell, PhD
JAMA. 2006;296:1775-1778.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The August 24, 2006, decision by the US Food and Drug Administration (FDA) to approve over-the-counter (OTC) sales of the emergency contraceptive Plan B—1.5 mg of levonorgestrel taken after unprotected sexual intercourse—was a major development in a long and contentious regulatory process. Since the drug is more effective the sooner it is used, the delay in obtaining it imposed by its prior prescription-only status limited its effectiveness.
In the interest of making Plan B available more quickly when needed, the distributor (Women's Capital Corp, Washington, DC) applied to the FDA in April 2003 for approval of OTC status. In December 2003, a joint FDA advisory committee voted 23-4 in favor of approval. It did so on the basis of evidence that the drug is both effective and safe and that it met all FDA criteria for OTC availability. The committee also took into account . . . [Full Text of this Article] Plan B's Pharmacologic and Clinical Properties
Author Affiliations: Editor Emeritus, Annals of Internal Medicine, and Executive Editor, Institute for Healthcare Improvement, Cambridge, Mass (Dr Davidoff); and Director, Office of Population Research, Princeton University, Princeton, NJ (Dr Trussell).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Emergency contraceptive use among 5677 women seeking abortion in Shanghai, China
Meng et al.
Hum Reprod 2009;24:1612-1618.
ABSTRACT
| FULL TEXT
Politics and science: a cautionary tale for the presidential candidates
Kamerow
BMJ 2008;337:a2093-a2093.
FULL TEXT
|
